Navigation Links
CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
Date:12/19/2007

BRANFORD, Conn., Dec. 19 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous belinostat, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of patients with previously-treated thymoma and thymic carcinoma. This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for belinostat.

The Phase II clinical trial is being led by Giuseppe Giaccone, M.D., Ph.D., Chief, Medical Oncology Branch/CCR/NCI in Bethesda, MD. Patients with either thymoma or thymic carcinoma who have received at least one prior platinum-containing chemotherapy regimen are eligible for enrollment. The trial utilizes a Simon 2-stage design and is expected to enroll up to 33 patients who will receive belinostat administered by intravenous infusion once daily for five days every three weeks. Patients will continue to receive treatment with belinostat until disease progression.

The primary objective of the study is to determine the objective response rate by RECIST criteria. Secondary endpoints include evaluation of the time to response, duration of response, progression-free and overall survival. The pharmacodynamic activity of belinostat will also be evaluated by assessment of protein expression, changes in p21 and protein hyperacetylation, and identification of chromosomal gains or losses. Patients will be enrolled at multiple sites in the United States.

"Several key targets of HDAC inhibition, includi
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
2. CuraGen Appoints Clinical Oncologist as VP of Medical Development
3. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 On Wednesday of ... gel to use Redox Signaling molecules, became available for purchase ... overwhelming. , "The way that RENU 28 works is, if ... slowing down of the rate of cellular renewal within your ... the increasing of that rate of cellular renewal. What RENU ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, Inc. ... a conference call to provide an update on ... Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) ... web cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference ... completion through September 2, 2014 at (888) 203-1112 ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
(Date:8/19/2014)... NJ (PRWEB) August 20, 2014 ... and regenerative medicine is an inadequate vascular supply. ... constructs and decellularized tissues is critical for successful ... have attempted to mitigate deficiencies in vascularization and ... adding scaffold bioactivity, optimizing scaffold design and architecture, ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Compound, 1-TDC, SAN DIEGO, Oct. 9 ... appointment of Dr. Thomas Van,Dyke to its Medical ... to,Imagenetix on their experimental compound, 1-TDC, for the ... is Professor, Department of,Periodontology and Oral Biology, Boston ...
... Oct. 9 BioElectronics,Corporation, (Pink Sheets: BIEL), ... has cleared ActiPatch for sale by its,distributor, ... that the experienced sales professionals of,Endotherapeutics will ... team has many decades of experience in ...
... Nanoscale devices present a unique challenge to any optical ... to travel in a straight line. , On the ... light between two surfaces very close together (sometimes as ... the light. Light behaves much differently on the nanoscale ...
Cached Biology Technology:Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetix's Medical Advisory Board 2Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetix's Medical Advisory Board 3Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Taming tiny, unruly waves for nano optics 2
(Date:8/20/2014)... Huntsman Cancer Institute (HCI) at the University of Utah ... that encodes BCR-ABL, the unregulated enzyme driving the blood ... Cancer Society, nearly 6,000 new cases of CML will ... called tyrosine kinase inhibitors (TKIs), target BCR-ABL and are ... CML but control it in a way that allows ...
(Date:8/20/2014)... image of the Para and Mato Grosso states of ... set in order to deforest the land. Deforestation is ... where the land is thereafter converted to a nonforest ... farms, ranches, or urban use. The herringbone-patterned tan lines ... in the middle of the image are evidence of ...
(Date:8/20/2014)... Cancer Research UK scientists have discovered that acral melanomas ... Bob Marley,s death are genetically distinct from other more ... is external) published in the journal Pigment Cell & ... palms of the hands, soles of the feet, nail-beds and ... types of melanoma, it,s not caused by UV damage from ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Scientists learn more about rare skin cancer that killed Bob Marley 2
... -- A few came. They ran. They left. As a ... training in 2008 in new running suits chosen after tests ... The experience was enough to make both the University ... unaware that it was InSport,s training clothes that they had ...
... A new book by researchers at the Hebrew ... mouse demonstrates a surprising similarity between mice and humans. ... a team from the Hebrew University Bone Laboratory consisting of ... and Dr. Yankel Gabet. Also participating in the writing of ...
... YORK (October 9, 2007) -- When its time for ... they head to where it is safest from predators ... study by the Wildlife Conservation Society. Published in ... that moose avoid predation of their calves by grizzly ...
Cached Biology News:Marines land at UO, leave with plans to wear Oregon-made training suits 2Marines land at UO, leave with plans to wear Oregon-made training suits 3Of mice and men: similarities between skeletons of both 2
...
SAPK/JNK Antibody...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Component in MasterPure™ Purification Kits...
Biology Products: